IL17A and skin basal cell carcinoma: The analysis also provides the molecular basis of potential utility of some groups of medications (ICI, IL-17 inhibitors, TGF-β inhibitors) in a selective subgroup of patients with BCC (patients with BCC-associated APC DELs exposed to lower levels of As).